Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCYC NASDAQ:EOLS NASDAQ:GOSS NASDAQ:SLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$4.90-0.8%$5.01$4.24▼$9.36$344.35M1.56403,081 shs318,718 shsEOLSEvolus$6.37+14.2%$4.72$3.86▼$12.15$367.47M1.28773,265 shs3.92 million shsGOSSGossamer Bio$0.34-4.1%$0.41$0.32▼$3.87$82.24M2.156.11 million shs4.34 million shsSLNSilence Therapeutics$7.14-2.1%$6.33$3.54▼$8.40$344.33M1.52428,197 shs120,876 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics0.00%+0.63%-4.95%-20.00%-48.39%EOLSEvolus0.00%+2.11%+32.26%+13.40%-55.88%GOSSGossamer Bio0.00%+6.11%-0.05%-86.15%-68.66%SLNSilence Therapeutics0.00%-8.82%+20.03%+47.31%+81.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$4.90-0.8%$5.01$4.24▼$9.36$344.35M1.56403,081 shs318,718 shsEOLSEvolus$6.37+14.2%$4.72$3.86▼$12.15$367.47M1.28773,265 shs3.92 million shsGOSSGossamer Bio$0.34-4.1%$0.41$0.32▼$3.87$82.24M2.156.11 million shs4.34 million shsSLNSilence Therapeutics$7.14-2.1%$6.33$3.54▼$8.40$344.33M1.52428,197 shs120,876 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics0.00%+0.63%-4.95%-20.00%-48.39%EOLSEvolus0.00%+2.11%+32.26%+13.40%-55.88%GOSSGossamer Bio0.00%+6.11%-0.05%-86.15%-68.66%SLNSilence Therapeutics0.00%-8.82%+20.03%+47.31%+81.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCYCBicycle Therapeutics 2.44Hold$14.00185.71% UpsideEOLSEvolus 2.50Moderate Buy$16.00151.18% UpsideGOSSGossamer Bio 2.20Hold$5.431,515.65% UpsideSLNSilence Therapeutics 2.57Moderate Buy$34.50383.19% UpsideCurrent Analyst Ratings BreakdownLatest GOSS, EOLS, SLN, and BCYC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2026BCYCBicycle Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/24/2026EOLSEvolus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026GOSSGossamer Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SLNSilence Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026BCYCBicycle Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026BCYCBicycle Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$13.00 ➝ $12.003/23/2026GOSSGossamer Bio Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral3/18/2026BCYCBicycle Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$44.00 ➝ $36.003/18/2026BCYCBicycle Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$11.00 ➝ $7.003/18/2026BCYCBicycle Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$12.00 ➝ $8.003/18/2026BCYCBicycle Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $15.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCYCBicycle Therapeutics$72.86M4.69N/AN/A$7.95 per share0.62EOLSEvolus$297.18M1.41N/AN/A($0.36) per share-17.69GOSSGossamer Bio$48.47M1.63N/AN/A($0.53) per share-0.63SLNSilence Therapeutics$560K602.18N/AN/A$1.32 per share5.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCYCBicycle Therapeutics-$218.96M-$3.15N/AN/AN/A-344.95%-35.74%-29.54%N/AEOLSEvolus-$51.64M-$0.81N/A127.40N/A-14.39%N/A-18.95%N/AGOSSGossamer Bio-$170.37M-$0.75N/AN/AN/A-351.49%N/A-75.50%5/12/2026 (Estimated)SLNSilence Therapeutics-$88.61M-$1.87N/AN/AN/A-15,851.88%-101.71%-55.53%5/14/2026 (Estimated)Latest GOSS, EOLS, SLN, and BCYC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026GOSSGossamer Bio-$0.18N/AN/AN/A$4.61 millionN/A5/14/2026Q1 2026SLNSilence Therapeutics-$0.1850N/AN/AN/A$1.26 millionN/A5/4/2026Q1 2026EOLSEvolus-$0.14-$0.16-$0.02-$0.16$72.52 million$73.14 million4/30/2026Q1 2026BCYCBicycle Therapeutics-$0.6209-$0.87-$0.2491-$0.87$7.50 million$0.89 million3/18/2026Q4 2025BCYCBicycle Therapeutics-$1.00-$0.29+$0.71-$0.29$7.08 million$47.96 million3/17/2026Q4 2025GOSSGossamer Bio-$0.20-$0.21-$0.01-$0.21$7.53 million$13.80 million3/6/2026Q4 2025SLNSilence Therapeutics-$0.32-$0.25+$0.07-$0.27$2.19 million$0.03 million3/3/2026Q4 2025EOLSEvolus$0.09$0.0020-$0.0880N/A$89.58 million$90.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCYCBicycle TherapeuticsN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/ASLNSilence TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCYCBicycle TherapeuticsN/A12.6612.66EOLSEvolusN/A1.901.54GOSSGossamer BioN/A2.642.64SLNSilence TherapeuticsN/A8.728.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCYCBicycle Therapeutics86.15%EOLSEvolus90.69%GOSSGossamer Bio81.23%SLNSilence Therapeutics98.73%Insider OwnershipCompanyInsider OwnershipBCYCBicycle Therapeutics8.50%EOLSEvolus6.10%GOSSGossamer Bio7.20%SLNSilence Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCYCBicycle Therapeutics24069.71 million63.78 millionOptionableEOLSEvolus17065.86 million61.09 millionOptionableGOSSGossamer Bio180234.70 million217.80 millionOptionableSLNSilence Therapeutics10047.23 million45.30 millionNot OptionableGOSS, EOLS, SLN, and BCYC HeadlinesRecent News About These CompaniesSilence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 3 at 4:47 AM | americanbankingnews.comSilence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Short Interest Up 13.3% in AprilMay 1, 2026 | marketbeat.comSilence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Rating of "Moderate Buy" by BrokeragesApril 28, 2026 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Shares Down 1.8% - Here's What HappenedApril 25, 2026 | marketbeat.comSilence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?April 16, 2026 | zacks.comSilence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 5, 2026 | finance.yahoo.comWall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?March 5, 2026 | zacks.comSilence Therapeutics CEO Craig Tooman to end employmentDecember 15, 2025 | msn.comSilence Therapeutics Announces Leadership ChangesDecember 15, 2025 | businesswire.comSilence Therapeutics: Divesiran Targets High-Burden PVNovember 18, 2025 | seekingalpha.comSilence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsNovember 6, 2025 | msn.comSilence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsNovember 6, 2025 | businesswire.comIs Silence Therapeutics (NASDAQ:SLN) In A Good Position To Deliver On Growth Plans?October 17, 2025 | finance.yahoo.comSilence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comSilence Therapeutics to Participate in September Investor ConferencesSeptember 2, 2025 | businesswire.comSilence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 7, 2025 | businesswire.comSilence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia VeraJune 12, 2025 | businesswire.comWall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a BetJune 6, 2025 | zacks.comWall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to TradeMay 21, 2025 | zacks.comSilence Therapeutics plc GAAP EPS of -C$0.20May 8, 2025 | seekingalpha.comSilence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of DirectorsMay 6, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGOSS, EOLS, SLN, and BCYC Company DescriptionsBicycle Therapeutics NASDAQ:BCYC$4.90 -0.04 (-0.81%) Closing price 04:00 PM EasternExtended Trading$4.90 +0.00 (+0.10%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Evolus NASDAQ:EOLS$6.37 +0.79 (+14.16%) Closing price 04:00 PM EasternExtended Trading$6.17 -0.20 (-3.20%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Gossamer Bio NASDAQ:GOSS$0.34 -0.01 (-4.11%) Closing price 04:00 PM EasternExtended Trading$0.34 +0.00 (+0.60%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Silence Therapeutics NASDAQ:SLN$7.14 -0.15 (-2.06%) Closing price 04:00 PM EasternExtended Trading$7.13 -0.01 (-0.14%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
